Status:
COMPLETED
Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
Lead Sponsor:
Leuko Labs, Inc.
Collaborating Sponsors:
M.D. Anderson Cancer Center
Center for Advancing Point of Care Technologies
Conditions:
Hematologic Malignancy
Eligibility:
All Genders
7-39 years
Brief Summary
Single-site non-significant risk, open-label clinical investigation designed to validate the usability, adherence, and preliminary diagnostic performance of a novel technology to detect neutropenia. S...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Study subjects, or their parent/legal guardian for subjects \<18 years, must be able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations. Subjects between the ages of 7 and 17.9 years must provide assent.
- Male or Female aged 7 years to 65 years.
- Adults (\> 18 years) diagnosed Diagnosed with Hodgkin/Non-Hodgkin Lymphoma or breast cancer.
- Children and adolescents (7 - 18 years) with liquid or solid tumors.
- Scheduled treatment with cytotoxic chemotherapy with an associated high/intermediate risk of neutropenia (table 1) 30.
- Able (in the investigator's opinion) and willing to comply with all study requirements.
- Exclusion Criteria
- Participants with amputations, congenital malformations, or any severe abnormalities of the hands as determined by the investigator.
- Participants with a history of vasculitis, Raynaud syndrome, scleroderma, mixed connective tissue disease, or any other rheumatologic systemic condition that could produce microcirculatory changes in the nailfold.
- Participants with circulating tumor cells in previous or current lab determinations.
- Adult (\>18 years) participants with leukemia of all types and pediatric (7-18 years) participants with leukemia that are either not in remission or in the minimal residual disease category.
- Participants with any condition producing significant tremor (e.g., essential tremor, Parkinson´s disease, dystonic tremor).
- Unstable participants (pediatric or adults) or adult participants with hypotension (systolic blood pressure \<90 and diastolic blood pressure \< 60mmHg).
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrolment.
Exclusion
Key Trial Info
Start Date :
September 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04889937
Start Date
September 7 2021
End Date
July 31 2023
Last Update
March 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030